“Natural” does not tell you the risks of a peptide product. Peptides are chains of amino acids; the term describes a molecule’s structure. It does not establish that every peptide has the same effects or safety profile.[1]
The more useful question is what is known about the specific product and the use being proposed.
Safety always has a context
FDA explains that an approved medicine’s benefits must outweigh its risks for the use under review. Approval does not mean a drug has no side effects. Its labeling describes the approved use and information needed for safer use.[2]
Assessing safety requires evidence about the administered product: the formulation, route, amount studied and people receiving it. FDA’s clinical-research process investigates how a drug behaves in people and gathers information about adverse effects.[3]
A short study may identify common, immediate problems while leaving less common or longer-term effects uncertain. Larger and longer later-stage studies can detect effects that smaller early trials miss.[3]
The finished product matters too
Compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness or quality before they are marketed, although compounding can meet a medical need for an individual patient.[4]
The ingredient’s name, the evidence for the intended use and the quality of the finished preparation all contribute separate information.
